ReviewJournal of neurovirology2007
Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease.
Review in Journal of neurovirology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Neruodevelopmental Outcomes in Preschool Children Living With HIV-1 Subtypes A and D in Uganda.The Pediatric infectious disease journal · 2018Trial
- Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study.Journal of neurovirology · 2010Trial
- Neurocognitive Complications of HIV Infection in Low-Income Countries.Current topics in behavioral neurosciences · 2021Article
- Functional impact of HIV-1 Tat on cells of the CNS and its role in HAND.Cellular and molecular life sciences : CMLS · 2020Review
- Phylogeny of partialHeliyon · 2020Article
- Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease.Frontiers in microbiology · 2015Review
- Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Effects of Tat proteins and Tat mutants of different human immunodeficiency virus type 1 clades on glial JC virus early and late gene transcription.The Journal of general virology · 2013Article
- Neuropsychological outcomes in adults commencing highly active anti-retroviral treatment in South Africa: a prospective study.BMC infectious diseases · 2012Article
- Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.PloS one · 2011Article
- HIV-1 nef protein structures associated with brain infection and dementia pathogenesis.PloS one · 2011Article
- HIV-miR-H1 evolvability during HIV pathogenesis.Bio Systems · 2010Article
- Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.Journal of the International AIDS Society · 2010Article
- Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.Biomarkers in medicine · 2009Article
- HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2009Article
- HIV infection and the central nervous system: a primer.Neuropsychology review · 2009Review
- Neuropsychological assessment of HIV-infected populations in international settings.Neuropsychology review · 2009Review
- Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report.Retrovirology · 2008Article
- Effects of antiretroviral therapy on cognitive impairment.Current HIV/AIDS reports · 2008Review
- Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes.PloS one · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the many variables affecting transmission and pathogenesis of the human immunodeficiency virus type 1(HIV-1), the effects of HIV subtypes, or clades, on disease progression remain unclear. Although debated, some studies have found that the variable env and pol sequences of different subtypes of HIV-1 may endow some subtypes with greater degrees of cell tropism, virulence, and drug resistance, which may lead to differences in overall disease progression. HIV-associated dementia (HAD) appears to be associated with viral diversity and markers of immune activation. Africa has the highest prevalence of HIV, largest viral diversity, and is where clade recombination occurs most frequently. All of these factors would suggest that HAD would pose the largest threat in this region of the world. Although investigations into the effects of different subtypes on overall disease progression are well documented, few have looked into the effects of subtypes on neurological disease progression. This review highlights the need for more international research involving the neurological effects and especially the clinical presentation of dementia for the entire range of the group M HIV-1 subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.